RECEPTOR.AI provides the tools for building customizable AI workflows to approach drug discovery projects of any complexity. Our next-generation platform for drug discovery is not only AI-powered but also AI-automated and AI-assisted. receptor.ai/materials/

There is a certain disappointment in #AI drug discovery among early adopters of this technology. However, the confidence in AI solutions could be restored by providing the users with correct tools, which answer the correct questions. medium.com/receptor-ai/ca…

Receptor.AI drug discovery platform is built from the ground up to automate the AI-based drug discovery workflow and to allow all members of R&D team to concentrate on strategic goals. medium.com/receptor-ai/da…

RECEPTOR.AI SaaS Platform for AI-based drug discovery was validated on BRD4 protein, which is a target to fight leukaemia. medium.com/receptor-ai/de…

We are proud to share a comparative study of Receptor.AI virtual screening platform against 24 competing techniques, which shows an excellent performance of our technology that is on par or superior to all of its rivals. medium.com/receptor-ai/th… #AI #DrugDiscovery

RECEPTOR.AI aims to democratize drug discovery, making its AI platform accessible to SMEs and academia. To demonstrate our platform's strength we are offering 5 organizations an access to it for free! linkedin.com/pulse/receptor…

DNA-Encoded Libraries (DELs) is one of the most powerful technologies in drug discovery. However, its combination with AI techniques could be even more successful. medium.com/receptor-ai/ai… #MachineLearning #Artificialntelligence

Receptor.AI helps fight obesity by acting on the ‘sixth taste’ receptors. link.medium.com/JfrD9HdQtwb

The lipid membranes are druggable and available for AI-based drug design. link.medium.com/9bJGjfLXwwb

Receptor.AI’s end-to-end drug discovery platform avoids computational overkill and embraces experimental feedback. link.medium.com/y2S4irCQtwb

Receptor.AI introduces 3DProtDTA — the next generation drug-target interaction AI model link.medium.com/kKxCiQIMGwb

Developing bifunctional protein degraders for difficult-to-drug proteins with the Receptor.AI link.medium.com/Ttfd145K2wb

Identification of dual-targeting Mycobacterium tuberculosis aminoacyl-tRNA synthetase inhibitors… link.medium.com/rSwfvXFUdxb

The rock-solid base for Receptor.AI platform: benchmarking the drug-target interaction AI model link.medium.com/wjnvW2pvayb

The key for fast and efficient drug discovery: benchmarking the Receptor.AI ADMET prediction model link.medium.com/nTekOStICyb

AI-based prediction of small molecules’ selectivity for highly similar protein variants link.medium.com/WLSJrFX0Qzb

Targeting cryptic pockets with Receptor.AI drug discovery platform link.medium.com/Av2JmSiTzAb

We are excited to announce that our CEO, Dr. Alan Nafiiev (Alan Nafiiev), will present at NVIDIA GTC! Join us for 'Advancing Drug Design with Generative AI: BioNeMo Workflow,' March 21, 1:00 p.m. CET. Explore the future of healthcare. #GTC24 Register: nvda.ws/3URaeFX

Launching ArtiDock 2.0! A breakthrough in AI docking: unmatched precision & speed. Revolutionizing virtual screening, ArtiDock 2.0 redefines efficiency and hit identification. Join us in leading pharma innovation! Find out more: biorxiv.org/content/10.110… #ArtiDock #Innovation

Excited to announce Dr. Alan Nafiev represented us at Nvidia GTC on Mar 21, discussing the topic of "Advancing Drug Design with Generative AI." A big thanks to NVIDIA GTC for hosting the conference and everyone who joined us! #NvidiaGTC #GenerativeAI #DrugDesign #Innovation